RESUMEN
Thalidomide developed in 1954 for morning sickness had proven to be a teratogen and hence was withdrawn from market. Resurgence of thalidomide began as an immunomodulator when it was shown to be effective in the management of multiple myeloma and many conditions like erythema nodosum leprosum, graft versus host disease, recurrent aphthous ulcers etc. We report a case of Stevens Johnson syndrome-toxic epidermal necrolysis developing in an elderly male who was prescribed thalidomide after being diagnosed with multiple myeloma.
Asunto(s)
Inhibidores de la Angiogénesis/efectos adversos , Mieloma Múltiple/tratamiento farmacológico , Síndrome de Stevens-Johnson/etnología , Talidomida/efectos adversos , Anciano , Inhibidores de la Angiogénesis/administración & dosificación , Antineoplásicos/administración & dosificación , Antineoplásicos/efectos adversos , Humanos , Masculino , Talidomida/administración & dosificaciónRESUMEN
BACKGROUND: Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis are severe cutaneous reactions caused by certain drugs, including antiepileptic carbamazepine. A strong association has been reported between human leucocyte antigen (HLA)-B*1502 and carbamazepine-induced SJS in Han Chinese patients. European studies suggested that HLA-B*1502 is not a universal marker but is ethnicity-specific for Asians. AIM: To study the association between HLA-B*1502 and carbamazepine-induced SJS in Indian patients. METHODS: Eight individuals who fulfilled the diagnostic criteria of SJS induced by carbamazepine were identified and HLA-B molecular typing was performed. HLA-B genotyping was carried out by polymerase chain reaction using sequence-specific primers. RESULTS: Out of eight patients studied for genotype, six patients were found to have the HLA-B*1502 allele. CONCLUSION: This study suggests an association between HLA-B*1502 and carbamazepine-induced SJS in Indian patients.